No abstract

Little is known about emissions and exposure potential from vat polymerization additive manufacturing, a process that uses light-activated polymerization of a resin to build an object. Five vat polymerization printers (three stereolithography (SLA) and two digital light processing (DLP) were evaluated individually in a 12.85 m 3 chamber. Aerosols (number, size) and total volatile organic compounds (TVOC) were measured using real-time monitors. Carbonyl vapors and particulate matter were collected for offline analysis using impingers and filters, respectively. During printing, particle emission yields (#/g printed) ranged from 1.3 ± 0.3 to 2.8 ± 2.6 × 10 8 (SLA printers) and from 3.3 ± 1.5 to 9.2 ± 3.0 × 10 8 (DLP printers). Yields for number of particles with sizes 5.6 to 560 nm (#/g printed) were 0.8 ± 0.1 to 2.1 ± 0.9 × 10 10 and from 1.1 ± 0.3 to 4.0 ± 1.2 × 10 10 for SLA and DLP printers, respectively. TVOC yield values (μg/g printed) ranged from 161 ± 47 to 322 ± 229 (SLA printers) and from 1281 ± 313 to 1931 ± 234 (DLP printers). Geometric mean mobility particle sizes were 41.1-45.1 nm for SLA printers and 15.3-28.8 nm for DLP printers. Mean particle and TVOC yields were statistically significantly higher and mean particle sizes were significantly smaller for DLP printers compared with SLA printers (p < 0.05). Energy dispersive X-ray analysis of individual particles qualitatively identified potential occupational carcinogens (chromium, nickel) as well as reactive metals implicated in generation of reactive oxygen species (iron, zinc). Lung deposition modeling indicates that about 15-37% of emitted particles would deposit in the pulmonary region (alveoli). Benzaldehyde (1.0-2.3 ppb) and acetone (0.7-18.0 ppb) were quantified in emissions from four of the printers and 4-oxopentanal (0.07 ppb) was detectable in the emissions from one printer. Vat polymerization printers emitted nanoscale particles that contained potential carcinogens, sensitizers, and reactive metals as well as CONTACT A. B. Stefaniak,

, +1(704)687-5177 1. Introduction 2. Pyridine-type ligands 2.1 Complexes with pyridine 2.2 Complexes with pyridine-2-thiolate 3. Quinolate-type ligands 3.1 Complexes with oxyquinolate 3.2 Complexes with thioquinolate 3.3 Complexes with (2-N-(quinoline-8-yl)iminomethylphenolate) 4. Polypyridine-type ligands 4.1 Complexes with just one bipyridine or phenanthroline ligand 4.2 Complexes with two bipyridine or phenanthroline ligands 4.3 Complexes with three bipyridine or phenanthroline ligands 5. Conclusion and Future Outlook

At present, including failed attempts, it takes about 15 years and costs totaling up to $2.6 billion to take a promising new compound from laboratory to the market. Increasing drug resistance among microbial pathogens has led to a growing interest in exploring novel methods to enhance the efficacy of existing drugs. Combination therapies involving two or more known antimicrobial methods, particularly those involving nanoparticles for combating the clinical problems associated with antibiotic resistance, have been garnering interest. In the current study, we determined whether a combination therapy involving silver nanoparticles, which are known for their antimicrobial activity, and the widely used antibiotic ampicillin can be effective against methicillin-resistant Staphylococcus aureus (MRSA). In the presence of sub-lethal dose of silver nanoparticles, ampicillin was found to be effective against MRSA. Indeed, the results show that silver nanoparticles and ampicillin act synergistically, with the effect being more pronounced when a lower concentration of ampicillin is present. When present at a higher concentration, ampicillin coats the silver nanoparticle, preventing the direct interaction of nanoparticles and bacteria. This study discusses the possible applications of combination antimicrobial therapies involving silver nanoparticles for therapeutic treatments.

No abstract